Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Peter Feinberg, a director of Immuneering Corp (IMRX), reported a purchase of 5,000 Class A common shares on 09/29/2025 at a price of $7.18 per share. After the transaction he beneficially owns 141,766 shares directly, plus additional indirect holdings through entities (392,242; 476,615; 115,441), as listed on the Form 4. The filing was signed by an attorney-in-fact on 09/30/2025. This Form 4 discloses an insider purchase that increases the reporting person’s stake but contains no other financial metrics or commentary.
Immuneering Corporation (IMRX) is offering 18,959,914 shares of Class A common stock at $9.23 per share, with underwriters able to purchase up to 2,843,987 additional shares. Net proceeds from the offering and a contingent concurrent private placement with Aventis Inc., a Sanofi subsidiary, are estimated at approximately $187.4 million (about $212.0 million if the underwriters exercise their option). The company reported updated interim Phase 1/2a atebimetinib data: in 34 first-line pancreatic cancer patients dosed at 320 mg once daily with mGnP, 86% overall survival and 53% progression-free survival at nine months (median PFS 9.6 months; median OS not reached) with a median follow-up of nine months; Grade ≥3 treatment-emergent adverse events included anemia in 24% and neutropenia in 18% of patients and no Grade 5 TEAEs. Proceeds are intended to advance development and are projected to fund operations into 2029 based on current plans. The private placement of up to $25.0 million is contingent on a qualified public offering of at least $75.0 million and includes customary ownership limits and lock-up/standstill provisions.
Immuneering Corporation entered into an underwriting agreement to sell 18,959,914 shares of its Class A common stock at $9.23 per share in a public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to 2,843,987 additional shares. All shares are being sold by the company.
Concurrently, Immuneering agreed to a $25.0 million private placement with Aventis Inc., a Sanofi subsidiary, under which Aventis will purchase 2,708,559 Class A shares at the same price, contingent on the closing of the public offering. The company expects net proceeds of about $164.1 million from the offering and $23.3 million from the private placement, to fund preclinical and clinical development, working capital, and general corporate purposes.
Immuneering states that its cash, cash equivalents, marketable securities and these net proceeds should fund operations into 2029. In connection with the deal, it reduced the capacity of its existing $100,000,000 at-the-market program by $1,250,007 to $98,749,993 and suspended sales under that ATM amount.
Immuneering Corporation (IMRX) is offering shares of its Class A common stock and pre-funded warrants, with a concurrent private placement with Aventis Inc., a wholly owned subsidiary of Sanofi, to purchase up to $25.0 million of stock contingent on a firm-commitment public offering that raises at least $75.0 million.
Clinical update: in a 320 mg once-daily atebimetinib plus modified gemcitabine/nab-paclitaxel cohort (N=34, cutoff August 26, 2025), Immuneering reported 86% overall survival and 53% progression-free survival at nine months, median PFS 9.6 months, median OS not reached; six-month rates were 94% OS and 70% PFS. Grade ≥3 TEAEs ≥10% included anemia (24%) and neutropenia (18%); no Grade 5 TEAEs reported.
The company’s Class A common stock trades on Nasdaq under IMRX (last reported sale $8.59 on September 23, 2025). Underwriters will receive a 6.0% commission and an option to purchase additional shares. The private placement shares will not be registered and are expected to close concurrent with the qualified public offering.
Immuneering Corporation (IMRX) is offering shares of its Class A common stock and pre-funded warrants, with a concurrent private placement with Aventis Inc., a wholly owned subsidiary of Sanofi, to purchase up to $25.0 million of stock contingent on a firm-commitment public offering that raises at least $75.0 million.
Clinical update: in a 320 mg once-daily atebimetinib plus modified gemcitabine/nab-paclitaxel cohort (N=34, cutoff August 26, 2025), Immuneering reported 86% overall survival and 53% progression-free survival at nine months, median PFS 9.6 months, median OS not reached; six-month rates were 94% OS and 70% PFS. Grade ≥3 TEAEs ≥10% included anemia (24%) and neutropenia (18%); no Grade 5 TEAEs reported.
The company’s Class A common stock trades on Nasdaq under IMRX (last reported sale $8.59 on September 23, 2025). Underwriters will receive a 6.0% commission and an option to purchase additional shares. The private placement shares will not be registered and are expected to close concurrent with the qualified public offering.
Immuneering Corp (IMRX) reported safety and clinical development plans for atebimetinib in an 8-K filed September 24, 2025. In the 320 mg ITT population, treatment-emergent adverse events (TEAEs) occurring in <10% of patients included fatigue (6%), vomiting (3%), febrile neutropenia (3%), hypokalemia (3%) and nausea (3%). No Grade 5 TEAEs or new safety signals were identified.
The company expects regulatory feedback on pivotal Phase 3 trial plans in Q4 2025 and plans to announce updated overall survival (OS) and progression-free survival (PFS) data from 34 first-line pancreatic cancer patients treated with atebimetinib plus mGnP, including presentation at a 2026 scientific conference. Subject to regulatory feedback, Immuneering aims to initiate a pivotal Phase 3 trial by end-2025 and dose the first patient by mid-2026, and may add additional combination arms in 2026, including non-small cell lung cancer.
Immuneering Corp (IMRX) reported safety and clinical development plans for atebimetinib in an 8-K filed September 24, 2025. In the 320 mg ITT population, treatment-emergent adverse events (TEAEs) occurring in <10% of patients included fatigue (6%), vomiting (3%), febrile neutropenia (3%), hypokalemia (3%) and nausea (3%). No Grade 5 TEAEs or new safety signals were identified.
The company expects regulatory feedback on pivotal Phase 3 trial plans in Q4 2025 and plans to announce updated overall survival (OS) and progression-free survival (PFS) data from 34 first-line pancreatic cancer patients treated with atebimetinib plus mGnP, including presentation at a 2026 scientific conference. Subject to regulatory feedback, Immuneering aims to initiate a pivotal Phase 3 trial by end-2025 and dose the first patient by mid-2026, and may add additional combination arms in 2026, including non-small cell lung cancer.
Immuneering Corp (IMRX) filed a Form 144 reporting a proposed sale of 14,000 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ with an approximate sale date of 09/23/2025 and an aggregate market value of $136,080.00. The filing shows the shares were acquired in two open-market purchases: 8,000 shares on 03/18/2024 (paid in cash) and 6,000 shares on 03/15/2022 (paid in cash). The filer attests there is no material nonpublic information about the issuer and no securities were sold by the filer in the past three months according to the form.
Immuneering Corp (IMRX) filed a Form 144 reporting a proposed sale of 14,000 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ with an approximate sale date of 09/23/2025 and an aggregate market value of $136,080.00. The filing shows the shares were acquired in two open-market purchases: 8,000 shares on 03/18/2024 (paid in cash) and 6,000 shares on 03/15/2022 (paid in cash). The filer attests there is no material nonpublic information about the issuer and no securities were sold by the filer in the past three months according to the form.
Leah R. Neufeld, the company's Chief People Officer, reported the voluntary acquisition of 11,815 shares of Immuneering Corporation Class A Common Stock on September 15, 2025 under the company’s 2021 Employee Stock Purchase Plan (ESPP). The shares were purchased at a price of $1.428 per share, which reflects the ESPP pricing feature of at least 85% of the fair market value on the enrollment date for the relevant offering period.
Following the purchase, Ms. Neufeld beneficially owned 22,544 shares. The filing notes the transaction is exempt under Rule 16b-3(c). The Form 4 was executed by an attorney-in-fact and dated September 17, 2025.
Leah R. Neufeld, the company's Chief People Officer, reported the voluntary acquisition of 11,815 shares of Immuneering Corporation Class A Common Stock on September 15, 2025 under the company’s 2021 Employee Stock Purchase Plan (ESPP). The shares were purchased at a price of $1.428 per share, which reflects the ESPP pricing feature of at least 85% of the fair market value on the enrollment date for the relevant offering period.
Following the purchase, Ms. Neufeld beneficially owned 22,544 shares. The filing notes the transaction is exempt under Rule 16b-3(c). The Form 4 was executed by an attorney-in-fact and dated September 17, 2025.
Insider purchase under ESPP: Immuneering Corp Chief Accounting Officer Mallory Morales acquired 14,497 shares of Class A Common Stock on September 15, 2025 through the companys 2021 Employee Stock Purchase Plan at a price of $1.428 per share, representing an ESPP purchase for the offering period March 16, 2025September 15, 2025. After the purchase Morales beneficially owns 27,233 shares. The filing was signed by an attorney-in-fact on September 17, 2025 and notes the transaction is exempt under Rule 16b-3(c).
Insider purchase under ESPP: Immuneering Corp Chief Accounting Officer Mallory Morales acquired 14,497 shares of Class A Common Stock on September 15, 2025 through the companys 2021 Employee Stock Purchase Plan at a price of $1.428 per share, representing an ESPP purchase for the offering period March 16, 2025September 15, 2025. After the purchase Morales beneficially owns 27,233 shares. The filing was signed by an attorney-in-fact on September 17, 2025 and notes the transaction is exempt under Rule 16b-3(c).
Brett Matthew Hall, the company's Chief Scientific Officer and a director, reported an acquisition of 14,880 shares of Immuneering Corp Class A common stock under the company's Employee Stock Purchase Plan (ESPP). The shares were purchased on the ESPP purchase date at a price of $1.428 per share, and the reporting line shows total beneficial ownership of 374,198 shares following the transaction. The filing notes the purchase was made pursuant to the ESPP's terms, which provide for shares to be bought at no less than 85% of the fair market value determined at the enrollment date, and states the transaction is exempt under Rule 16b-3(c).
Brett Matthew Hall, the company's Chief Scientific Officer and a director, reported an acquisition of 14,880 shares of Immuneering Corp Class A common stock under the company's Employee Stock Purchase Plan (ESPP). The shares were purchased on the ESPP purchase date at a price of $1.428 per share, and the reporting line shows total beneficial ownership of 374,198 shares following the transaction. The filing notes the purchase was made pursuant to the ESPP's terms, which provide for shares to be bought at no less than 85% of the fair market value determined at the enrollment date, and states the transaction is exempt under Rule 16b-3(c).
Immuneering Corp filed a Form D claiming a Regulation D exemption for a private equity offering. The Delaware corporation, based in Cambridge, Massachusetts, reports a total offering amount of $24,998,919, with $24,998,919 sold and $0 remaining to be sold. The filing lists nine investors to date and states no sales commissions or finders' fees were paid. The offering is equity and related option/warrant securities, not tied to a business combination, and the issuer does not intend the offering to last more than one year. The filing was signed by CEO Benjamin J. Zeskind.